PeptidePros

Compare · Head-to-head

GHK-Cu vs MOTS-c.

Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.

Which should you research first?

Start with GHK-Cu, then use the table to confirm fit.

GHK-Cu is the cleaner first read based on the current evidence, risk, and regulatory data stored for this pair. The right answer can still change if your goal, sport testing status, vendor constraints, or monitoring tolerance makes the other option a better fit.

Comparison next step

Personalize this head-to-head.

Take the quiz before converting a comparison into a compound, vendor, or protocol decision.

01· Subject

GHK-Cu

Copper peptide complex with substantial topical/cosmetic literature for skin and hair repair.

Tier B-Cmed-high risk

02· Subject

MOTS-c

Mitochondrial-derived peptide studied in mouse models for metabolic homeostasis and insulin sensitivity.

Tier Chigh risk

01 · At a glance

Decision factorGHK-CuMOTS-c
Primary fittissue repair & recovery and longevity & anti-aging comparisonsfat loss & metabolism and longevity & anti-aging comparisons
EvidenceTier B-CTier C
Riskmed-highhigh
Experience levelbeginneradvanced
Budget tierbudgetpremium
Administration routetopicalsubcutaneous

02 · Use case & timing

Decision factorGHK-CuMOTS-c
Goal fitTissue Repair & Recovery, Longevity & Anti-Aging, Skin & HairFat Loss & Metabolism, Longevity & Anti-Aging
What users compare it forSkin repair, collagen stimulation, wound healing support (topical evidence).Preclinical: improved insulin sensitivity, metabolic regulation, exercise performance in mice.
Onset timelineSkin remodeling: weeks to months (collagen turnover cycles).Metabolic endpoints assessed over days to weeks in mice; exercise performance improvements after ~10 days.
Main tradeoffEvidence and product availability can still be uneven, so documentation matters more than hype.Potential upside comes with much more safety and screening caution than lower-risk alternatives.

03 · Safety & restrictions

Decision factorGHK-CuMOTS-c
Adverse effectsGenerally better tolerated topically than systemic peptides.FDA: no identified human exposure data; significant immunogenicity/characterization risks.
ContraindicationsCopper sensitivity.No human data.
Interaction notesUnknown clinically; avoid stacking claims.Unknown.
Regulatory statusNot approvedNot approved
FDA flagNo current flag notedFDA compounding caution
WADA statusNot listedStatus unclear

04 · Age & monitoring

Decision factorGHK-CuMOTS-c
Supported age ranges25-34, 35-44, 45-54, 55-64, 65+No age guidance yet
Life-stage noteBroad adult fit for cosmetic and skin-repair goals, especially when route is topical rather than systemic.Not yet documented
Monitoring burdenNot specifiedNot specified
Follow-up cadenceNot yet documentedNot yet documented

05 · Cost & sourcing

Decision factorGHK-CuMOTS-c
Typical cycle cost$60.00€33.02
Estimated monthly cost$60.00€33.02
Cost confidenceHigh confidenceHigh confidence

06 · Before you buy

Decision factorGHK-CuMOTS-c
Tracked vendor listings3 listings3 listings
Sourcing noteProduct format varies by listing, so double-check route, concentration, and presentation.Product format varies by listing, so double-check route, concentration, and presentation.
Stack-friendly?Usually stack-friendlyUsually stack-friendly

Sources and review notes

  1. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15

    Used for FDA compounding-risk context and peptide safety flags.

  2. The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15

    Used for athlete-facing WADA risk and peptide-class restrictions.

  3. Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15

    Used for broad peptide-therapeutics background and evidence framing.

Still deciding

Get a plan tailored to you.

The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.